Prohibitin Antibody (YA6276)

Prohibitin (PHB) is an evolutionarily conserved protein family composed of the closely related isoforms PHB1 and PHB2, which are predominantly localized to the inner mitochondrial membrane and form a heteromeric complex that preserves mitochondrial integrity and cellular homeostasis^[1][2]. Mechanistically, prohibitins regulate mitochondrial architecture, cristae morphogenesis, mitochondrial dynamics, and quality-control processes, thereby supporting cell survival and metabolic adaptation under stress conditions^[1][3][4]. Beyond mitochondria, PHB1 and PHB2 are distributed in the nucleus and plasma membrane, where they participate in transcriptional regulation and signal transduction pathways that influence proliferation, apoptosis, and cellular differentiation^[2][5]. A key biological distinction between the isoforms is that PHB2 functions as a mitophagy receptor through interaction with LC3 during mitochondrial depolarization, whereas PHB1 is more extensively characterized as a scaffold and signaling regulator associated with transcriptional control and membrane-associated signaling events^[2]. In disease contexts, dysregulated PHB1 and PHB2 expression has been reported in multiple cancers and is linked to tumor cell proliferation, apoptosis, migration, and metastasis through pathways including Raf-MEK-ERK signaling^[2][5]. Experimental studies further demonstrate that prohibitins contribute to neurodegenerative disease models by regulating mitochondrial function, neuronal survival, and mitochondrial quality control^[1][6]. For research applications, small-molecule ligands such as rocaglamide and fluorizoline directly target prohibitin proteins and disrupt PHB-dependent signaling, providing useful pharmacological tools for mechanistic studies and target validation in disease models^[5][2].